• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,569.39 827.57
( 1.08%)
Global Indices
Nasdaq
52,658.24 149.83
(0.29%)
Dow Jones
7,594.79 30.15
(0.40%)
Hang Seng
68,634.11 890.26
(1.31%)
Nikkei 225
10,498.02 25.57
(0.24%)
Forex
USD-INR
95.45 -0.01
(-0.01%)
EUR-INR
109.10 0.17
(0.15%)
GBP-INR
127.94 0.35
(0.28%)
JPY-INR
0.59 0.00
(0.03%)

EQUITY - MARKET SCREENER

Global Health Ltd
Industry :  Healthcare
BSE Code
ISIN Demat
Book Value()
543654
INE474Q01031
149.2385834
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MEDANTA
72.45
35938.75
EPS(TTM)
Face Value()
Div & Yield %
18.45
2
0.04
 

hdfc life insurance company ltd
Concord Biotech rallies after USFDA approval for Tofacitinib tablets
Jun 10,2026
Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular-course juvenile idiopathic arthritis.

According to market estimates, the US market size for Tofacitinib tablets across both strengths is approximately $500 million. The approval is expected to enable the company to tap this market opportunity, expand its product portfolio, and support its long-term growth strategy in the US and other international markets.

Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide.

The company’s consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25.